ENGINEERING – IMPLEMENTATION – QUALITY
Advancing radiochemistry innovation
We support customers in developing production processes for radionuclides and radiopharmaceuticals by solving complex challenges in process development, engineering and implementation
WHAT FUTURECHEMISTRY IS
Supporting engineering team for innovation and implementation
We help translate radiochemistry into practical and robust production processes by solving complex challenges at the intersection of chemistry, engineering and quality.
We do not develop medicinal-product candidates or conduct preclinical and clinical development.
OUR EXPERTISE
Support in every stage of radiochemical development
From feasibility to implementation, supporting each project with the expertise it needs
Technical feasibility and concept development
Assessing technical opportunities, defining development strategies, and designing process and equipment concepts.
Radiochemical process development
Developing radiochemical processes for source material extraction, target processing, radionuclide purification, radiolabelling and quality control.
Equipment development and automation
Integrating fluidic, mechanical and automated control systems for radiochemical production.
Implementation and production readiness
Preparing processes, equipment and operators for qualified and reliable production.
Typical customer challenges
Questions we help resolve
How can this radiochemical process be made reproducible and scalable?
How can automated equipment meet critical parameters in our radiolabelling protocol?
At what stage of our process does GMP compliance become relevant?
Is this new radionuclide purification process technically and financially viable?
Latest resources
Work, news and technical perspectives.
Meet FutureChemistry at EANM 2026.
Let’s connect in Vienna! Our team is looking forward to engaging with fellow experts in radiochemistry, radioisotope production and radiopharmaceutical development.
Connect on LinkedInSeparating astatine-211 and polonium-210 via dry distillation
A new literature highlight shared by Dion van der Born.
View on LinkedInTerbium-161 and lutetium-177 labelled GRPR antagonists
A literature highlight shared by Dion van der Born.
View on LinkedInLET’S TALK
Working on a new radiochemical production process?
Facing a complex development challenge?
Ready to move from concept to production?
Tell us the radionuclide, project stage, current challenge and intended outcome.